Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: A total population-based case-control study

JAMA Neurology

Volumn 72, Issue 1, 2015, Pages 40-48

  Lin, Feng Cheng ^a,b   Tsai, Ching Piao ^c   Lee, Johnny Kuang Wu ^d   Wu, Ming Tsang ^a,e   Lee, Charles Tzu Chi ^e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Pingtung Hospital   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d UNIVERSITY OF TAIPEI   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; STEROID;

ADOLESCENT; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT; POPULATION RESEARCH; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; AGED; DISABILITY; DOSE RESPONSE; HEALTH CARE PLANNING; MIDDLE AGED; PUBLIC HEALTH; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TAIWAN; TREATMENT OUTCOME;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME;

EID: 84921038538     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.3367     Document Type: Article

References (41)

1. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68(13):1002-1007.
2. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
3. Heiman-Patterson TD, Miller RG. NIPPV: a treatment for ALS whose time has come. Neurology. 2006;67(5):736-737.
4. Zoccolella S, Beghi E, Palagano G, et al; SLAP registry. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007;14(3):262-268.
5. Rilutek (riluzole)may extend survival in amyotrophic lateral sclerosis. J Neurosci Nurs. 1996; 28(4):275.
6. Fondell E, O'Reilly EJ, Fitzgerald KC, et al. Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler. 2012;13(6):573-579.
7. Bredesen DE. Neural apoptosis. Ann Neurol. 1995; 38(6):839-851.
8. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004; 63(7):1324-1325.
9. Gao Y, O'Caoimh R, Healy L, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013;3(7): pii:e002881.
10. AbdAlla S, Langer A, Fu X, Quitterer U. ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's disease. Int J Mol Sci. 2013;14(8):16917-16942.
11. Reardon KA, Mendelsohn FA, Chai SY, Horne MK. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease.Aust N Z J Med. 2000;30(1): 48-53.
12. Iwasaki Y, Ichikawa Y, Igarash O, Ikeda K, Kinoshita M. Influence of temocapril on cultured ventral spinal cord neurons. Neurochem Res. 2003; 28(5):711-714.
13. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124(suppl):96-107.
14. Zoccolella S, Beghi E, Serlenga L, Logroscino G. Classification of amyotrophic lateral sclerosis cases at presentation in epidemiological studies. Neurol Sci. 2005;26(5):330-333.
15. Beghi E, Balzarini C, Bogliun G, et al; Italian ALS Study Group. Reliability of the El Escorial diagnostic criteria for amyotrophic lateral sclerosis. Neuroepidemiology. 2002;21(6):265-270.
16. Tsai CP, Lin FC, Lee CT. Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study [published online April 14, 2014]. Mult Scler.
17. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004-1009.
18. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10 (3):253-263.
19. Gerber YN, Sabourin JC, Rabano M, Vivanco Md, Perrin FE. Early functional deficit and microglial disturbances in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2012;7(4):e36000.
20. Boillée S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312 (5778):1389-1392.
21. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol. 2007;6(4): 373-378.
22. Dong YF, Kataoka K, Tokutomi Y, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J. 2011;25(9):2911-2920.
23. Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48(5):629-641.
24. D'Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509-527.
25. Oeda T, Shimohama S, Kitagawa N, et al. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum Mol Genet. 2001;10(19):2013-2023.
26. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7(11):603-615.
27. Ravati A, Junker V, Kouklei M, Ahlemeyer B, Culmsee C, Krieglstein J. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999;373(1):21-33.
28. Mira ML, Silva MM, Queiroz MJ, Manso CF. Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic Res Commun. 1993;19(3):173-181.
29. Said Ahmed M, Hung WY, Zu JS, Hockberger P, Siddique T. Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. J Neurol Sci. 2000;176(2):88-94.
30. Liu D,Wen J, Liu J, Li L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999; 13(15):2318-2328.
31. Bartosz M, Kedziora J, Bartosz G. Antioxidant and prooxidant properties of captopril and enalapril. Free Radic Biol Med. 1997;23(5):729-735.
32. de Cavanagh EM, Fraga CG, Ferder L, Inserra F. Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am J Physiol. 1997;272 (2, pt 2):R514-R518.
33. Why HJ, Ansell H, Patel VB, et al. Antioxidant status in hypertension and effects of angiotensin converting enzyme inhibition. Biochem Soc Trans. 1995;23(2):224S.
34. Mantle D, Patel VB, Why HJ, et al. Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. Clin Chim Acta. 2000; 299(1-2):1-10.
35. Wang H, O'Reilly EJ, Weisskopf MG, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol. 2011; 173(6):595-602.
36. Michal Freedman D, Kuncl RW,Weinstein SJ, Malila N, Virtamo J, Albanes D. Vitamin E serum levels and controlled supplementation and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(4):246-251.
37. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994;330(9):613-622.
38. Corona JC, Tovar-y-Romo LB, Tapia R. Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis. Expert Opin Ther Targets. 2007;11(11):1415-1428.
39. Sengul G, Coskun S, CakirM, Coban MK, Saruhan F, Hacimuftuoglu A. Neuroprotective effect of ACE inhibitors in glutamate-induced neurotoxicity: rat neuron culture study. Turk Neurosurg. 2011;21(3):367-371.
40. Popat RA, Tanner CM, van den Eeden SK, et al. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(3):157-163.
41. de Jong SW, Huisman MH, Sutedja NA, et al. Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population-based study. Am J Epidemiol. 2012;176(3):233-239.